异基因造血干细胞移植后AML复发的危险因素分析及预测模型的构建
Analysis of Risk Factors for Relapse of AML after Allogeneic Hematopoietic Stem Cell Transplantation and Construction of Prediction Model
摘要: 目的:探讨急性髓系白血病(AML)患者接受异基因造血干细胞移植(allo-HSCT)后复发的影响因素,进而构建复发风险预测模型。方法:收集安徽医科大学第一附属医院行allo-HSCT的72例非M3型AML患者的临床资料,根据复发情况分为未复发组和复发组。通过单因素和多因素Logistic回归分析,筛选出影响移植后复发的独立危险因素,在此基础上构建并评价预测模型。结果:72例AML患者中,非复发组54例,复发组18例,多因素Logistic回归分析显示,染色体异常(P = 0.031)、移植前未缓解状态(P = 0.026)、移植后感染CMV (P = 0.032)是AML患者移植后复发的独立危险因素。构建预测模型的ROC曲线下面积为0.788 (95% CI: 0.673~0.902),校准曲线斜率接近1,H-L拟合优度检验显示χ2 = 0.446,P = 0.979,说明该模型区分度和校准度良好。结论:AML患者移植后复发的独立影响因素包括染色体异常、移植前未缓解状态及移植后感染CMV,据此构建的预测模型表现出较好的预测价值,可为临床识别高危复发患者提供重要参考。
Abstract: Objective: To investigate the factors influencing relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML), and establish a model to predict relapse risk. Method: The study included 72 patients with non-M3 AML who received their first allo-HSCT at the First Affiliated Hospital of Anhui Medical University. Patients were divided into a non-relapse group and a relapse group based on their post-transplantation status. Univariate and multivariate Logistic regression analysis is used to screen out the independent risk factors affecting relapse after transplantation, and establish a prediction model based on this analysis and evaluate the performance of the model prediction models. Result: Among 72 AML patients, 54 cases were in the non-relapsed group and 18 cases were in the relapsed group. Multivariate Logistic analysis showed that chromosome abnormality (P = 0.031), non-remission status prior to transplantation (P = 0.026), and CMV infection after transplantation (P = 0.032) were independent relapse risk factors. The area under the ROC curve of the constructed prediction model was 0.788 (95% CI: 0.673~0.902), the slope of the calibration curve was close to 1, and the results of H-L goodness of fit test showed χ2 = 0.446, P = 0.979, indicating that the model had good differentiation and calibration. Conclusion: The independent influencing factors of relapse after allo-HSCT in AML patients include chromosomal abnormality, non-remission state before transplantation, and CMV infection after transplantation. The prediction model constructed on this basis shows good predictive value, and can provide an important reference for identifying high-risk patients with relapse.
文章引用:吴梦如, 杨明珍. 异基因造血干细胞移植后AML复发的危险因素分析及预测模型的构建[J]. 临床医学进展, 2025, 15(6): 1043-1053. https://doi.org/10.12677/acm.2025.1561823

参考文献

[1] Loke, J., Malladi, R., Moss, P. and Craddock, C. (2019) The Role of Allogeneic Stem Cell Transplantation in the Management of Acute Myeloid Leukaemia: A Triumph of Hope and Experience. British Journal of Haematology, 188, 129-146. [Google Scholar] [CrossRef] [PubMed]
[2] Sterling, C. and Webster, J. (2020) Harnessing the Immune System after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia. American Journal of Hematology, 95, 529-547. [Google Scholar] [CrossRef] [PubMed]
[3] Falini, B. and Martelli, M.P. (2023) Comparison of the International Consensus and 5th WHO Edition Classifications of Adult Myelodysplastic Syndromes and Acute Myeloid Leukemia. American Journal of Hematology, 98, 481-492. [Google Scholar] [CrossRef] [PubMed]
[4] Rausch, C., Rothenberg-Thurley, M., Dufour, A., Schneider, S., Gittinger, H., Sauerland, C., et al. (2023) Validation and Refinement of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia. Leukemia, 37, 1234-1244. [Google Scholar] [CrossRef] [PubMed]
[5] Leukemia & Lymphoma Group, Chinese Society of Hematology and Chinese Medical Association (2021) [Chinese Guidelines for the Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Not APL) (2021)]. Chinese Journal of Hematology, 42, 617-623.
[6] Sauerer, T., Velázquez, G.F. and Schmid, C. (2023) Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Immune Escape Mechanisms and Current Implications for Therapy. Molecular Cancer, 22, Article No. 180. [Google Scholar] [CrossRef] [PubMed]
[7] Mohty, R., El Hamed, R., Brissot, E., Bazarbachi, A. and Mohty, M. (2023) New Drugs Before, During, and after Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia. Haematologica, 108, 321-341. [Google Scholar] [CrossRef] [PubMed]
[8] Kinsella, F.A.M., Maroto, M.A.L., Loke, J. and Craddock, C. (2024) Strategies to Reduce Relapse Risk in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukaemia. British Journal of Haematology, 204, 2173-2183. [Google Scholar] [CrossRef] [PubMed]
[9] Lin, C.H., Chen, T.C., Shih, Y.H., et al. (2022) Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution. Journal of International Medical Research, 50. [Google Scholar] [CrossRef] [PubMed]
[10] Abou Dalle, I., Labopin, M., Kröger, N., Schroeder, T., Finke, J., Stelljes, M., et al. (2023) Impact of Disease Burden on Clinical Outcomes of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 58, 784-790. [Google Scholar] [CrossRef] [PubMed]
[11] Wienecke, C.P., Heida, B., Venturini, L., Gabdoulline, R., Krüger, K., Teich, K., et al. (2024) Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. Blood, 144, 296-307. [Google Scholar] [CrossRef] [PubMed]
[12] Short, N.J., Fu, C., Berry, D.A., Walter, R.B., Freeman, S.D., Hourigan, C.S., et al. (2022) Association of Hematologic Response and Assay Sensitivity on the Prognostic Impact of Measurable Residual Disease in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Leukemia, 36, 2817-2826. [Google Scholar] [CrossRef] [PubMed]
[13] Buckley, S.A., Wood, B.L., Othus, M., Hourigan, C.S., Ustun, C., Linden, M.A., et al. (2017) Minimal Residual Disease Prior to Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia: A Meta-Analysis. Haematologica, 102, 865-873. [Google Scholar] [CrossRef] [PubMed]
[14] Moukalled, N., Labopin, M., Versluis, J., Socié, G., Blaise, D., Salmenniemi, U., et al. (2024) Complex Karyotype But Not Other Cytogenetic Abnormalities Is Associated with Worse Posttransplant Survival of Patients with Nucleophosmin 1‐mutated Acute Myeloid Leukemia: A Study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. American Journal of Hematology, 99, 360-369. [Google Scholar] [CrossRef] [PubMed]
[15] Peric, Z., Wilson, J., Durakovic, N., Ostojic, A., Desnica, L., Vranjes, V.R., et al. (2018) Early Human Cytomegalovirus Reactivation Is Associated with Lower Incidence of Relapse of Myeloproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Transplantation, 53, 1450-1456. [Google Scholar] [CrossRef] [PubMed]
[16] Turki, A.T., Tsachakis-Mück, N., Leserer, S., Crivello, P., Liebregts, T., Betke, L., et al. (2021) Impact of CMV Reactivation on Relapse of Acute Myeloid Leukemia after HCT Is Dependent on Disease Stage and ATG. Blood Advances, 6, 28-36. [Google Scholar] [CrossRef] [PubMed]
[17] Teira, P., Battiwalla, M., Ramanathan, M., Barrett, A.J., Ahn, K.W., Chen, M., et al. (2016) Early Cytomegalovirus Reactivation Remains Associated with Increased Transplant-Related Mortality in the Current Era: A CIBMTR Analysis. Blood, 127, 2427-2438. [Google Scholar] [CrossRef] [PubMed]